Keytruda ^*

Keytruda (generic name: pembrolizumab) is an immunotherapy used to treat several types of cancer. It targets and blocks the PD-1 (programmed death receptor-1) protein found on the surface of immune cells. By inhibiting PD-1, Keytruda enhances the immune system’s ability to detect and destroy cancer cells. Pembrolizumab is approved to treat various cancers, including advanced melanoma, non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), classical Hodgkin lymphoma (cHL), urothelial carcinoma, and others. It is classified as a monoclonal antibody specifically designed to bind to specific proteins on the surface of cancer cells or immune cells, enabling the body to fight tumors more effectively. As part of the immunotherapy class, Keytruda is often prescribed when traditional chemotherapy and radiation are not effective or as part of combination therapy for greater treatment efficacy. Monoclonal antibodies like Keytruda, denoted by the suffix “zumab,” belong to a family of medications that target specific antigens associated with diseases, particularly cancer. These antibodies are laboratory-produced molecules designed to serve as substitute antibodies, enhancing the immune system’s ability to fight off malignant cells. This family of drugs works by interfering with proteins or receptors that inhibit the immune system’s natural cancer-fighting responses. For instance, PD-1 inhibitors such as Keytruda prevent tumors from hiding from immune detection, allowing for a more robust immune response. Each “zumab” medication is tailored to address specific cancers or immune-related conditions by focusing on unique cellular markers.

Dosage

It is essential to follow the prescribed treatment schedule set by the healthcare provider. Keytruda is administered as a 30-minute intravenous (IV) infusion, typically every three or six weeks. The dosage varies depending on the type of cancer being treated, but the most common dosage is 200 mg every three weeks. The treatment schedule can vary, but it often continues until the disease progresses, unacceptable side effects develop, or the patient’s healthcare provider decides to discontinue the treatment.

Storage

The drug must be stored in a refrigerator between 2-8°C / 36-46°F and should not be frozen or shaken. If in any doubt, consult our blog on safe medicine management. It must be shipped cold, and a shipping fee will be applied at checkout.

Common Questions About Keytruda

How does Keytruda work in treating cancer?

Keytruda works by blocking the PD-1 protein on the surface of immune cells, allowing the immune system to detect and attack cancer cells more effectively. PD-1 normally helps keep the immune response in check, but in cancer, this protein can prevent the immune system from fighting the disease. By inhibiting PD-1, Keytruda enhances the immune system’s ability to destroy cancerous cells.

How is pembrolizumab administered?

Pembrolizumab is administered through an intravenous (IV) infusion over 30 minutes. The typical dosing schedule is either every three weeks or six weeks, depending on the specific condition being treated. The healthcare provider will determine the exact dosing and duration based on the type of cancer and the patient’s response to the treatment.

Can Keytruda be used for lung cancer?

Yes, Keytruda is being widely used to treat non-small cell lung cancer (NSCLC), especially when the cancer is advanced or has spread to other parts of the body. It is often prescribed either alone or in combination with chemotherapy, depending on the patient’s PD-L1 expression levels and other clinical factors.